Michael Rosenberg is an associate in Goodwin’s Business Law Department and a member of its Technology and Life Sciences groups. Mr. Rosenberg represents publicly and privately held corporations, investment banks, and venture capital firms focused on a variety of growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensing and strategic collaborations.

Mr. Rosenberg regularly advises both domestic and foreign issuers and investment banks in public and private offerings of equity and debt, including initial public offerings (IPOs), secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, 144A offerings, registered direct offerings, and PIPEs, as well as seed financings and later-stage venture capital financings.

Mr. Rosenberg also advises corporate clients on a broad range of securities law and corporate governance matters, Securities and Exchange Commission (SEC) compliance, as well as domestic, cross-border, private and public mergers and acquisitions.

Areas of Practice
Domaines D’Expertise





Mr. Rosenberg has advised on a number of deals in the public and private sectors, including:

  • Kaleido Biosciences in its $75 million initial public offering on Nasdaq in the U.S.;
  • SpringWorks Therapeutics in its $125 million Series B financing to advance two late-stage rare disease oncology programs toward potential regulatory approval;
  • Zealand Pharma’s $205 million of certain royalty rights to Royalty Pharma;
  • Navitor Pharmaceuticals in its Series C financing and issuance of convertible notes;
  • Advaxis Inc. in its $20 million shelf offering
  • Stifel, Nicolaus & Company, Incorporated as Sole Bookrunning Manager in a follow on offering for IntriCon Corporation.
  • Oppenheimer & Co. as Sole Bookrunning Manager in a follow-on offering for BioLineRx Ltd.
  • Imara Pharma in its $63 million Series B financing
  • Forward Pharma A/S’s IPO on Nasdaq in the U.S., which won M&A Advisor’s “Healthcare/Life Sciences Sector Deal of the Year” award*
  • AM-Pharma’s sale of a minority interest in the company to Pfizer Inc. and related option payment, which was a finalist for the 2015 Scrip Awards*
  • Zealand Pharma’s IPO on Nasdaq in the U.S*
  • Edge Therapeutics’ IPO on Nasdaq in the U.S.*
  • Iconix Brand Group, Inc.’s offering of High Yield Convertible Notes*
  • Griffon Corporation’s 144A Offering of High Yield Debt Securities*
  • U.S. Shale Solutions, Inc. in the 144A offering in Senior Secured Notes.*
  • Dava Pharmaceuticals in its sale to Endo Pharmaceuticals.*

* Denotes experience prior to joining Goodwin.

Prior to joining Goodwin, Mr. Rosenberg was an associate in the New York offices of three international law firms.

Professional Experience

Mr. Rosenberg was a member of the Fordham Moot Court and the Fordham Journal of Corporate and Financial Law.

In The News









J.D., 2009
Fordham University School of Law
B.A., 2006
Yeshiva University
(magna cum laude)



New Jersey
New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique